Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 1 August 2026.
Announcements
388
Total raised
£13.0B
disclosed amounts
Octopus Ventures led the Series B round with backing from Sonae IM and others.
"Junk mail through our letterboxes has now been replaced by a deluge of messages and notifications, whether through email, text, WhatsApp, Instagram or a dozen other channels,"
Beringea led the Series B round, with participation from Felix Capital, JamJar Investments and Downing Ventures.
"Taymoor has rapidly built Papier into the destination for personalised stationery products, developing a remarkable team and a curated collection of designs to inspire a growing community of hundreds of thousands of stationery lovers around the world. Beringea has backed the vision and growth of the business and we will now work closely with Taymoor to scale an international success story."
The financing round was led by SBI Group and will support the company's growth in Asia and product development.
Oxygen House led a £20m Series B round in Exeter-based learning technology company Sparx.
"Oxygen House is a dynamic group of companies and we are delighted to have their backing. From day one they have shown a strong belief in our vision for Sparx. This new investment will help us to firmly position Sparx at the forefront of edtech and build on the success we have already achieved with our partner schools. The ongoing support of Oxygen House will enable us to have a significant impact on education nationally and beyond the UK."
The round was led by BGF with participation from Parkwalk, Cambridge Enterprise, and Cambridge Innovation Capital.
"Parkwalk are delighted to continue to support the ground breaking technology from Dr Ken Smith’s laboratory at Addenbrookes, which enables the prognosis of IBD and an earlier clinical decision as to the correct drug treatment. This will significantly improve clinical outcomes and enhance patient welfare. The team at PredictImmune have done a magnificent job in productising the technology and are now taking the tests on their commercial pathway. We look forward to seeing the platform extended to benefit clinical outcomes in further diseases."
